RESHAPE LIFESCIENCES INC (RSLS) Stock Price, Forecast & Analysis

NASDAQ:RSLS • US76090R3093

3.92 USD
+0.72 (+22.5%)
At close: Aug 14, 2025
3.22 USD
-0.7 (-17.86%)
After Hours: 8/14/2025, 8:00:01 PM

RSLS Key Statistics, Chart & Performance

Key Statistics
Market Cap81.26M
Revenue(TTM)7.17M
Net Income(TTM)-3.46M
Shares20.73M
Float2.13M
52 Week High303.25
52 Week Low1.87
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-212.11
PEN/A
Fwd PEN/A
Earnings (Next)11-12
IPO2016-10-06
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
RSLS short term performance overview.The bars show the price performance of RSLS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 -50

RSLS long term performance overview.The bars show the price performance of RSLS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RSLS is 3.92 USD. In the past month the price increased by 37.54%. In the past year, price decreased by -98.49%.

RESHAPE LIFESCIENCES INC / RSLS Daily stock chart

RSLS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to RSLS. When comparing the yearly performance of all stocks, RSLS is a bad performer in the overall market: 99.02% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
RSLS Full Technical Analysis Report

RSLS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RSLS. The financial health of RSLS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RSLS Full Fundamental Analysis Report

RSLS Financial Highlights

Over the last trailing twelve months RSLS reported a non-GAAP Earnings per Share(EPS) of -212.11. The EPS increased by 93.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.42%
ROE -281.54%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%114%
Sales Q2Q%-42.75%
EPS 1Y (TTM)93.64%
Revenue 1Y (TTM)-13.93%
RSLS financials

RSLS Forecast & Estimates

For the next year, analysts expect an EPS growth of 20% and a revenue growth 20% for RSLS


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y20%
Revenue Next Year20%
RSLS Analyst EstimatesRSLS Analyst Ratings

RSLS Ownership

Ownership
Inst Owners0.73%
Ins Owners0.06%
Short Float %N/A
Short RatioN/A
RSLS Ownership

RSLS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.62195.936B
ISRG INTUITIVE SURGICAL INC47.53172.536B
SYK STRYKER CORP24.21139.985B
BSX BOSTON SCIENTIFIC CORP21.34110.826B
IDXX IDEXX LABORATORIES INC42.4850.254B
BDX BECTON DICKINSON AND CO11.1650.113B
EW EDWARDS LIFESCIENCES CORP25.5244.027B
RMD RESMED INC20.5736.792B
GEHC GE HEALTHCARE TECHNOLOGY1636.615B
DXCM DEXCOM INC27.7327.309B

About RSLS

Company Profile

RSLS logo image ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Company Info

RESHAPE LIFESCIENCES INC

1001 Calle Amanecer

San Clemente CALIFORNIA 92673 US

CEO: Andrew Rasdal

Employees: 17

RSLS Company Website

RSLS Investor Relations

Phone: 19494296680

RESHAPE LIFESCIENCES INC / RSLS FAQ

What does RSLS do?

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.


What is the stock price of RESHAPE LIFESCIENCES INC today?

The current stock price of RSLS is 3.92 USD. The price increased by 22.5% in the last trading session.


Does RSLS stock pay dividends?

RSLS does not pay a dividend.


How is the ChartMill rating for RESHAPE LIFESCIENCES INC?

RSLS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is RESHAPE LIFESCIENCES INC (RSLS) stock traded?

RSLS stock is listed on the Nasdaq exchange.